Major Growth Boosting Factors:
Expected Growth in Revenue Generation:
The global human organoids market size is estimated to be USD 850 million in 2020 and projected to reach USD 1,901 million by 2025, at a CAGR of 17.5%.
The study involved four major activities to estimate the current size of the human organoids market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.
Demand for liver transplants result in the segment occupying the high share of the human orgnaoids market
Liver segment owes a good market share in Human Orgnaoids market. The large share of this segment is attributed to factors such as the advancements in technology among researchers and academia (coupled with growing industry-academia collaborations for organoids research, rising numbers of liver transplants and the investments by the both private and public players in the market.
Kidney estimated to be the growing market
The kidney human orgnaoids market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of transplant procedures), and an increasing number of life science researches in the field of specific requirements and treatment, especially across emerging countries.
Asia Pacific likely to emerge as the fastest growing clinical microbiology market, globally
Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR of 18.8% from 2020 to 2025. Government efforts to increase awareness related to human organoids; supportive regulations for the development and commercialization of advanced human orgnaoids products; rising healthcare expenditure; the increasing number of hospitals in India and China; expanding research base across India, China, and Japan; and the increasing incidence of transpalnts are driving the growth of the APAC clinical microbiology market.
Leading Companies Operating in the Global Market:
Prominent players in this market BioIVT (US), Thermo Fisher Scientific (US), ZenBio (US), Corning (US), Organovo (US), Cyprio (France), Biopredic International (France), CELLINK (Sweden), Emulate (US), Hµrel Corporation (US), InSphero (Switzerland), Kerafast (US), Kirkstall (UK), and MIMETAS (Netherlands).